Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...

At a median follow-up of 17 months, median PFS was estimated at beyond 19.3 months, with a 6-month PFS ... as well as by downstream signaling." Thus, the researchers hypothesized adding PI3K ...

Promising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor ...

Pfizer is wrapping up its lucrative goodbye to Haleon, raising approximately $3.3 billion by offloading its remaining 7.3% ...

In work conducted by Jining Medical University investigators, synthesis and optimization of a previously reported ...

GlaxoSmithKline has agreed a $3.3 billion takeover of US biotech Affinivax ... years has been dominated by Pfizer's Prevnar franchise. GSK said it is paying $2.1 billion upfront for Cambridge ...

GSK has news on that front today, as well, reporting that the phase 2/3 COSTAR trial of Jemperli with experimental TIM-3 antagonist cobolimab will move into the phase 3 stage on the advice of its ...

Targeted inhibition of a "signal jammer" protein may improve how tumors respond to immunotherapy. Published today in Nature, ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

Palmitic acid, the most common saturated fatty acid in a high fat diet, has been shown to impair insulin signaling. Recent pre-clinical work showed that BP1001-A attenuated palmitic acid-induced ...